BSE - Delayed Quote INR

Mercury Laboratories Limited (MERCURYLAB.BO)

846.55
-31.25
(-3.56%)
At close: 3:25:27 PM GMT+5:30
Loading Chart for MERCURYLAB.BO
  • Previous Close 877.80
  • Open 877.80
  • Bid 839.20 x --
  • Ask 857.00 x --
  • Day's Range 813.00 - 890.00
  • 52 Week Range 736.00 - 930.00
  • Volume 350
  • Avg. Volume 278
  • Market Cap (intraday) 1.016B
  • Beta (5Y Monthly) 0.38
  • PE Ratio (TTM) 25.72
  • EPS (TTM) 32.92
  • Earnings Date May 14, 2025
  • Forward Dividend & Yield 3.50 (0.40%)
  • Ex-Dividend Date Sep 20, 2024
  • 1y Target Est --

Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides pharmaceutical products for PCOS and uterine disorders, galactagogue, haemostat, iron, pain management, preterm labor management, antiemetic, PPI, vitamin K1, zinc supplement, vitamin D3, digestive enzyme, promolact, and childcare, as well as products for gynec, pediatric, surgeon, and physician applications. The company export its products comprising anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cough and cold, miscellaneous, and other formulations, as well as antibiotic, antifungal, and antiviral formulations to approximately 25 countries, including the Philippines, Myanmar, Sri Lanka, Vietnam, Cambodia, D.R. Congo, Ghana, Nigeria, Mozambique, Zambia, Kenya, lvory Coast, Mauritania, Burundi, Togo, Guatemala, Costa Rica, Peru, Ecuador, the United Kingdom, the United States, Moldova, and Jamaica. Mercury Laboratories Limited was founded in 1962 and is headquartered in Vadodara, India.

www.mercurylabs.com

482

Full Time Employees

March 31

Fiscal Year Ends

Recent News: MERCURYLAB.BO

View More

Performance Overview: MERCURYLAB.BO

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

MERCURYLAB.BO
5.52%
S&P BSE SENSEX (^BSESN)
4.08%

1-Year Return

MERCURYLAB.BO
7.83%
S&P BSE SENSEX (^BSESN)
11.25%

3-Year Return

MERCURYLAB.BO
7.83%
S&P BSE SENSEX (^BSESN)
54.05%

5-Year Return

MERCURYLAB.BO
7.83%
S&P BSE SENSEX (^BSESN)
161.32%

Compare To: MERCURYLAB.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MERCURYLAB.BO

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    1.05B

  • Enterprise Value

    1.07B

  • Trailing P/E

    26.70

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.47

  • Price/Book (mrq)

    2.04

  • Enterprise Value/Revenue

    1.49

  • Enterprise Value/EBITDA

    12.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.49%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    718.09M

  • Net Income Avi to Common (ttm)

    39.45M

  • Diluted EPS (ttm)

    32.92

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    26.66M

  • Total Debt/Equity (mrq)

    8.90%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: MERCURYLAB.BO

View More

Company Insights: MERCURYLAB.BO

Research Reports: MERCURYLAB.BO

View More

People Also Watch